CJC-1295 DAC (2mg) + Ipamorelin Stack
Components: CJC-1295 DAC + Ipamorelin
A GH secretagogue stack combining CJC-1295 DAC (2mg vial, once weekly) and Ipamorelin (5mg vial, once daily). DAC provides sustained GHRH stimulation while Ipamorelin delivers daily selective GH pulses.
Stack Components
This stack uses 2 separate vials — each peptide is reconstituted independently.
| Peptide | Dose | Frequency | Timing | Route |
|---|---|---|---|---|
| CJC-1295 DAC Long-acting GHRH analogue with albumin-binding DAC moiety; sustains elevated GH and IGF-1 for 6u20138 days per injection | 1000 mcg (1 mg) once weekly | Once weekly | Consistent day each week | SubQ |
| Ipamorelin Selective ghrelin receptor agonist; triggers GH pulses without significant cortisol or ACTH elevation | 100 mcg (Weeks 1u20132) u2192 150 mcg (Weeks 3u20134) u2192 200 mcg (Weeks 5+) | Once daily | Before bed u2014 aligns with natural nocturnal GH pulse | SubQ |
Reconstitution Guide
Each peptide in this stack is a separate vial. Reconstitute them one at a time using the parameters below.
CJC-1295 DAC
SubQIpamorelin
SubQAlways use bacteriostatic water to reconstitute each vial. Draw from separate vials — do not mix in the same syringe unless your protocol specifies a shared injection.
Protocol Timeline
Full 8–16 weeks cycle breakdown.
CJC-1295 DAC: 1000 mcg (40 units, 0.40 mL) once weekly. Ipamorelin: 100 mcg (6 units) once daily before bed. First CJC-1295 DAC injection establishes elevated GH/IGF-1 baseline lasting approximately 6u20138 days.
CJC-1295 DAC: continue 1000 mcg once weekly. Ipamorelin: advance to 150 mcg (9 units) once daily. Body composition changes begin to appear u2014 improved recovery and early lean mass development.
CJC-1295 DAC: continue 1000 mcg once weekly. Ipamorelin: advance to 200 mcg (12 units) once daily. Sustained GH elevation from CJC-1295 DAC combined with daily Ipamorelin pulses drives progressive body composition improvement.
Both peptides continue at established doses. Assess for any signs of water retention or other GH-related effects. End with a 4-week break before repeating.
Synergy Notes
CJC-1295 DAC's Drug Affinity Complex (DAC) moiety binds serum albumin, extending its half-life to approximately 6–8 days — providing a steady GHRH background that primes the pituitary for the entire week. Ipamorelin's daily pre-sleep administration then triggers amplified nocturnal GH pulses through the complementary ghrelin receptor pathway. The combination of sustained GHRH stimulation plus daily GHRP pulsing produces greater total GH output than either agent alone.
What to Expect
Weeks 1–3: Improved sleep quality and depth. Weeks 4–8: Progressive lean mass improvement and fat reduction. Weeks 9–16: Continued body composition changes, improved skin quality and recovery. Water retention is possible in the first 2–4 weeks and typically resolves.
Questions about CJC-1295 DAC (2mg) + Ipamorelin Stack
CJC-1295 DAC contains a Drug Affinity Complex that binds to serum albumin, extending its half-life to approximately 6u20138 days u2014 allowing once-weekly dosing. CJC-1295 without DAC has a half-life of roughly 30 minutes and requires daily or twice-daily dosing for equivalent coverage.
They can be drawn into the same syringe for a single injection on the weekly administration day. On other days, only Ipamorelin is injected.
The CJC-1295 + Ipamorelin combination is one of the most commonly studied GH secretagogue stacks and is considered intermediate in complexity. The once-weekly CJC-1295 DAC injection simplifies the schedule compared to daily CJC-1295 No DAC protocols.
Research Use Disclaimer
This content is for educational purposes only and does not constitute medical advice. For research use only.